Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+100.00%
vs the sector median at left
Aardvark Therapeutics, Inc. Common Stock
Market Cap
$110.30M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$109.14M
Net Profit Margin
-2955.63%
TTM Avg
-2231.78%
3Y Avg
-3480.44%
5Y Avg
-3216.57%
Market Cap
$112.57M
Net Profit Margin
-1030.42%
TTM Avg
-1409.68%
3Y Avg
-958.30%
5Y Avg
-801.33%
Market Cap
$112.94M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-1605.97%
5Y Avg
-1070.65%
Market Cap
$107.17M
Net Profit Margin
-14.78%
TTM Avg
-35.00%
3Y Avg
-39.46%
5Y Avg
-38.67%
Market Cap
$107.09M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-1332.08%
Market Cap
$106.98M
Net Profit Margin
-33.92%
TTM Avg
-11.74%
3Y Avg
-13.15%
5Y Avg
-11.88%
Market Cap
$106.96M
Net Profit Margin
-4416.22%
TTM Avg
-2208.11%
3Y Avg
-1104.06%
5Y Avg
-736.04%
Market Cap
$106.93M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $110.30M | 0.00% | 0.00% | 0.00% | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $109.14M | -2955.63% | -2231.78% | -3480.44% | -3216.57% |
| Caribou Biosciences, Inc. (CRBU)vs › | $112.57M | -1030.42% | -1409.68% | -958.30% | -801.33% |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.94M | 0.00% | 0.00% | -1605.97% | -1070.65% |
| Apyx Medical Corporation (APYX)vs › | $107.17M | -14.78% | -35.00% | -39.46% | -38.67% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $107.09M | 0.00% | 0.00% | 0.00% | -1332.08% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.98M | -33.92% | -11.74% | -13.15% | -11.88% |
| Outlook Therapeutics, Inc. (OTLK)vs › | $106.96M | -4416.22% | -2208.11% | -1104.06% | -736.04% |
| Vivani Medical, Inc. (VANI)vs › | $106.93M | 0.00% | 0.00% | 0.00% | 0.00% |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | -270.22% | -342.92% | -204.73% | -136.49% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
